Phage display technique is a powerful approach for discovering new tumor-and organ-targeting ligands,and radiolabeled phage has a potential to analyze the phage-binding sensitivity and specific imaging.In this study,phage Ⅱ (the spleen-targeting phage) in mice was isolated after three rounds biopanning,and labeled by 99mTc using mercaptoacetyltriglycine (MAG3) as chelator to evaluate their binding properties in vivo.The amount of phage Ⅱ eluted from spleen was enriched by plague assay each round.99mTc-MAG3-phage Ⅱ showed the less retention in blood at any time point than half that of 99mTc-MAG3-phage Ⅰ (the radiolabeled original Ph.D-12 phage as control).The accumulation in spleen between 99mTc-MAG3-phage Ⅰ and Ⅱ was of different tendency.The highest uptake of 99mTc-MAG3-phage Ⅱ in spleen was 24.80 %ID/g at 30 min;and of 99mTc-MAG3-phage I,30.93% ID/g at 5 min.After circulating 99mTc-MAG3-phage Ⅱ for 120 min,its accumulation in spleen decreased though higher than that of 99mTc-MAG3-phage Ⅰ.In other organs,the 99mTc-MAG3-phage Ⅱ showed low retention and high spleen-to-organ or tissue ratios.In conclusion,the radiolabeled phage Ⅱ is convenient for studying the binding and specificity of spleen-targeting peptides found via phage display in vivo.
The cyclic peptide YG5 and the t-butyloxycarbonyl(Boc)-modified analog(Boc-YG5) were labeled with radioiodine.The radiochemical purity of 131I-YG5 or 131I-Boc-YG5 was almost 100% after purification by RP-HPLC.Biodistribution in BALB/C nude mice bearing MCF-7 tumor was measured.After t-butyloxycarbonyl(Boc)-modification,the 131I-Boc-YG5 was quite resistant to deiodination in vivo,resulting in negligible radioactivity accumulation in thyroid.The radiotracer clearance in tumor became faster,the absolute tumor uptake decreased for 131I-Boc-YG5,but the tumor-to-tissue uptake ratios increased.The uptake ratios of tumor to muscle,blood,heart,and lung at 1 h post injection reached 4.73,1.70,4.09 and 1.70,respectively.It is demonstrated that Boc-group is an effective prosthetic one to prevent deiodination in vivo and improve tumor imaging for radioiodinated NGR.
A novel histidine derivative containing 4-nitroimidazole,(S)-2-(4-((4-nitro-1H-imidazol-1-yl) methyl) benzamido)-3-(1H-imidazol-4-yl)propanoic acid (His-NI),was synthesized and labeled with [99mTc(CO)3(H2O)3]+.The tricarbonyl technetium complex,the 99mTc(CO)3-His-NI,showed a 99% yield under mild conditions at a low His-NI ligand concentration of 10-4 molL-1,and its biodistribution in mice bearing S180 tumor had a selective accumulation in tumor (2.01±0.40%ID/g at 1 h postinjection) and a slow clearance.The tumor/muscle ratio was 1.64 at 1 h,3.10 at 4 h,and 3.88 at 24 h,indicating that the 99mTc(CO)3-His-NI has a potential to image tumor hypoxia.
